

Cover Story
																				By Matthew Bin Han Ong
In an era of intensifying judicial repudiation of evidence-based guidelines and deepening public mistrust toward science, America’s screening rate for cervical cancer has been declining. 
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
 - Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
 - Duke brain cancer researcher Kyle Walsh named director of NIEHS
 - Cancer centers adapt to life without site visits as NIH changes CCSG review
 - Trump cuts IVF drug deal with Merck in exchange for tariff exemption
 - Jonathan Licht named president, chief scientific officer at Van Andel Institute
 
            















